Comparative Pharmacology
Head-to-head clinical analysis: ANNOVERA versus SEASONIQUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANNOVERA versus SEASONIQUE.
ANNOVERA vs SEASONIQUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive containing segesterone acetate, a progestin, and ethinyl estradiol, an estrogen. Segesterone acetate suppresses gonadotropin release, preventing ovulation; ethinyl estradiol contributes to contraceptive efficacy by stabilizing the endometrium and inhibiting gonadotropin secretion.
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) that inhibits ovulation by suppressing gonadotropin-releasing hormone (GnRH), follicle-stimulating hormone (FSH), and luteinizing hormone (LH); increases cervical mucus viscosity and alters endometrial receptivity.
One vaginal ring inserted and left in place for 3 weeks, followed by a 1-week ring-free interval. Each ring releases ethinyl estradiol 0.024 mg/day and segesterone acetate 0.15 mg/day over 21 days.
One tablet daily orally: 84 days of ethinyl estradiol 0.02 mg / levonorgestrel 0.1 mg (active), followed by 7 days of ethinyl estradiol 0.01 mg.
None Documented
None Documented
Terminal half-life of etonogestrel (ENG): ~25 hours; ethinylestradiol (EE): ~12 hours; steady-state achieved after 7-14 days.
Ethinyl estradiol: approximately 15.9 hours (range 9-28 hours); Levonorgestrel: approximately 24.4 hours (range 12-48 hours). Terminal elimination half-life accounts for steady-state attainment within 5-7 days.
Renal: ~60% as metabolites; fecal: ~35% as metabolites; biliary: minor.
Renal: approximately 60% (as glucuronide and sulfate conjugates); Fecal: approximately 40% (as metabolites, with enterohepatic recycling).
Category C
Category C
Contraceptive
Contraceptive, Combination Hormonal